Literature DB >> 27750241

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.

Tomoyuki Nagai, Tokuzo Arao, Kazuto Nishio, Kazuko Matsumoto, Satoru Hagiwara, Toshiharu Sakurai, Yasunori Minami, Hiroshi Ida, Kazuomi Ueshima, Naoshi Nishida, Kazuko Sakai, Nagahiro Saijo, Kanae Kudo, Hiroyasu Kaneda, Daisuke Tamura, Keiichi Aomatsu, Hideharu Kimura, Yoshihiko Fujita, Seiji Haji, Masatoshi Kudo.   

Abstract

BACKGROUND: Epithelial-mesenchymal transition (EMT) is considered to play a critical role in cancer progression and metastasis. However, the impact of EMT on the prognosis of hepatocellular carcinoma (HCC) is still elusive. In this study, we examined the relationship between the expression of EMT markers and recurrence-free survival (RFS) and overall survival (OS) in HCC patients after hepatic resection.
SUMMARY: The mRNA expression of 15 genes related to EMT was assessed by quantitative real-time polymerase chain reaction in cancerous tissues from 72 patients who underwent hepatic resection of HCC between January 2005 and December 2010 at our hospital. The upregulation of TWIST and the downregulation of tight junction protein ZO-1 (TJP1) were significantly associated with shorter RFS as well as OS. Increased levels of TWIST and decreased levels of TJP1 should be predictive markers for poor prognosis in patients with HCC after hepatectomy; those could serve as potential biomarkers for the treatment of HCC. Key Messages: A low level of TJP1 and high level of TWIST expression were prognostic factors predicting HCC after hepatic resection.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27750241     DOI: 10.1159/000448860

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

Review 1.  Role of zonula occludens in gastrointestinal and liver cancers.

Authors:  Amit Kumar Ram; Balasubramaniyan Vairappan
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

2.  IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression.

Authors:  Yuan Gao; Tianping Luo; Xiwu Ouyang; Chunfu Zhu; Junqiang Zhu; Xihu Qin
Journal:  Oncol Lett       Date:  2020-05-30       Impact factor: 2.967

3.  miR-431-5p alters the epithelial-to-mesenchymal transition markers by targeting UROC28 in hepatoma cells.

Authors:  Qinglei Kong; Jianhua Han; Hong Deng; Feilong Wu; Shaozhong Guo; Zhiqiang Ye
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

4.  microRNA-16 Via Twist1 Inhibits EMT Induced by PM2.5 Exposure in Human Hepatocellular Carcinoma.

Authors:  Hao Zhang; Zhihu Li
Journal:  Open Med (Wars)       Date:  2019-09-15

Review 5.  Ten years of research on the role of BVES/ POPDC1 in human disease: a review.

Authors:  Ping Han; Yu Lei; Dongxiao Li; Jingmei Liu; Wei Yan; Dean Tian
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

Review 6.  Tight Junction Proteins and the Biology of Hepatobiliary Disease.

Authors:  Natascha Roehlen; Armando Andres Roca Suarez; Houssein El Saghire; Antonio Saviano; Catherine Schuster; Joachim Lupberger; Thomas F Baumert
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 7.  Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.

Authors:  Edda Russo; Camila Fiorindi; Francesco Giudici; Amedeo Amedei
Journal:  World J Hepatol       Date:  2022-02-27

8.  Epithelial-Mesenchymal Transition Markers in HCVAssociated Hepatocellular Carcinoma: A Multivariate Follow Up Study.

Authors:  Thanaa Elsayed Helal; Ahmed Aref; Asmaa Ibrahim Gomaa; Ola Nada; Mohamed Abd-Elghaffar; Khaled Farouk; Nermine Ahmed Ehsan
Journal:  Asian Pac J Cancer Prev       Date:  2022-03-01

9.  Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma.

Authors:  Amit Kumar Ram; Biju Pottakat; Balasubramaniyan Vairappan
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.